Opendata, web and dolomites

PLATELYS

PlateLys: The innovative human platelet lysate especially designed to maximize the effectiveness of cell-based therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PLATELYS project word cloud

Explore the words cloud of the PLATELYS project. It provides you a very rough idea of what is the project "PLATELYS" about.

ongoing    transmission    complete    certified    point    hormones    sacrificed    implanted    quality    culture    fetuses    engineered    sera    powder    cow    patented    fda    therapeutic    cultured    disease    2017    immune    gmp    billion    patient    combining    portfolio    formulation    standardized    platome    substantial       million    therapies    platelet    cross    previously    inhumanely    period    founders    inactivated    clinical    14    300    start    shift    leverage    amenable    approved    2025    viral    substitute    human    lysates    calf    date    market    solution    starting    award    winning    native    grade    flexibility    reactions    expand    serum    area    nonviable    fulfilling    collect    icelandic    lysate    cell    environment    animal    ups    cells    seek    created    52    oriented    profile    leads    endanger    negatives    mad    lethal    source    optimization    mimic    highest    cagr    safety    supplements    hpl    remarkable    indispensable    borne    platelys    2021    operators    vitro    turnover    staff    worth    acute    tissue    unprecedented    diseases    stem    thanks    2016    maximal    patients    cellular    isolated    commercialization    fast    species   

Project "PLATELYS" data sheet

The following table provides information about the project.

Coordinator
PLATOME LIFTAEKNI EHF 

Organization address
address: ALFASKEIDI 27
city: HAFNARFJORDUR
postcode: 220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Project website https://platome.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PLATOME LIFTAEKNI EHF IS (HAFNARFJORDUR) coordinator 50˙000.00

Map

 Project objective

Cellular therapies making use of stem cells, engineered immune cells or engineered tissue represent an unprecedented and fast-growing therapeutic area. To date, 14 cell therapies have been approved by the FDA. However, the cells being implanted to the patient need to be cultured in vitro at some point under highly specific and controlled conditions. One of these conditions –indispensable to culture any type of isolated cell in vitro– involves using animal-derived serum as a source of hormones and growth factors to mimic cells' native environment. It is estimated 1.5 million calf fetuses are inhumanely sacrificed to collect serum. This leads (among other negatives) to endanger patient's safety, because of cross-species immune reactions (which may be lethal) and the transmission of animal borne diseases (e.g. the mad cow disease). PlateLys is PLATOME´s solution to develop and produce a remarkable human-based serum substitute fulfilling all the requirements to culture cells. PLATOME is an award-winning Icelandic start-up created in 2016 to leverage the substantial know-how on human platelet lysates (hPL) production from its founders. PlateLys is the only hPL combining: a viral-inactivated hPL ensuring the highest safety profile for patients and operators; a clinical-grade lysate with standardized quality control and GMP certified amenable for research and clinical set-ups; a powder formulation providing maximal flexibility, especially on applications that were nonviable previously. The market of sera supplements will be worth €1.14 billion by 2025 (CAGR of 8%, period 2017-2025) with a large shift to hPL use ongoing. Through the PlateLys project we seek to complete the optimization and scale-up production, starting commercialization activities in Europe by 2021. By 2025, we will have generated €5.52 million in turnover and increase our staff by 300%. PlateLys will allow us to expand our portfolio of cell-oriented products, thanks to our patented production technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PLATELYS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PLATELYS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More